CSI 2021: COMPASS Trial: How it has Changed Life? |
News and Updates
eMediNexus Coverage from: 
CSI 2021: COMPASS Trial: How it has Changed Life?
Dr J Ezhilan, Chennai,  26 January 2022
Coronavirus Live Count Map India

remove_red_eye 2311 Views
COVID-19 Vaccine Updates


#Multispeciality

2 Read Comments                

The COMPASS trial for the first time has shown that dual pathway inhibition with low-dose rivaroxaban and aspirin has a favorable benefit risk profile in patients with polyvascular disease like CAD, PAD and cerebrovascular disease.

Since benefit is seen more in <65-year population than >65-year population, Indian patients who are younger will benefit more from the dual pathway inhibition therapy.

To comment on this article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now